Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14- eicosatetraenoic acid-induced vascular dysfunction: Role of inhibitor of κb kinase

Hypertension

Volumn 57, Issue 4, 2011, Pages 788-794

  Wu, Cheng Chia ^a   Cheng, Jennifer ^a   Zhang, Frank Fan ^a   Gotlinger, Katherine H ^a   Kelkar, Mukul ^a   Zhang, Yilun ^a   Jat, Jawahar L ^b   Falck, John R ^b   Schwartzman, Michal L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

20 HETE; androgen; cytochrome P450; IKK; NF B

Indexed keywords

20 HYDROXY 5,8,11,14 EICOSATETRAENOIC ACID; 20 HYDROXYEICOSADIENOIC ACID; ACETYLCHOLINE; ANDROGEN; ANDROSTANOLONE; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; ICOSATETRAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PARTHENOLIDE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; KIDNEY ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; VASOCONSTRICTION; VASODILATATION;

ANDROGENS; ANIMALS; BLOOD PRESSURE; DIHYDROTESTOSTERONE; ENDOTHELIUM, VASCULAR; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; I-KAPPA B KINASE; RATS; RATS, SPRAGUE-DAWLEY; RENAL ARTERY; SESQUITERPENES; VASOCONSTRICTION;

EID: 79953210320     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.161570     Document Type: Article

References (41)

1. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208. (Pubitemid 34163570)
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
3. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;5:952-959. (Pubitemid 351398967)
4. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340. (Pubitemid 36724373)
5. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008;31:71-79. (Pubitemid 351630063)
6. Chen YF, Meng QC. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci. 1991;48: 85-96.
7. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension. 2000;35:480-483. (Pubitemid 30054220)
8. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31:435-439.
9. Crofton JT, Ota M, Share L. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J Hypertens. 1993; 11:1031-1038. (Pubitemid 23307874)
10. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension. 1997;29:494-499. (Pubitemid 27074089)
11. Ouchi Y, Share L, Crofton JT, Iitake K, Brooks DP. Sex difference in the development of deoxycorticosterone-salt hypertension in the rat. Hypertension. 1987;9:172-177. (Pubitemid 17027831)
12. Ashton N, Balment RJ. Sexual dimorphism in renal function and hormonal status of New Zealand genetically hypertensive rats. Acta Endocrinol. 1991;124:91-97.
13. Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA. 2001; 98:5211-5216. (Pubitemid 32397108)
14. Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 2008;60: 29-37. (Pubitemid 351586540)
15. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA Jr, Schwartzman ML. 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2008;294:H1018-H1026. (Pubitemid 351253316)
16. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 2007;50:123-129. (Pubitemid 46986020)
17. Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, Roman RJ. 20-HETE is an endogenous inhibitor of the large-conductance Ca2-activated K- channel in renal arterioles. Am J Physiol. 1996;270: R228-R237.
18. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 2005;41:175-193. (Pubitemid 41596358)
19. Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 2008;324: 103-110. (Pubitemid 350294158)
20. Cheng J, Wu CC, Gotlinger KH, Zhang F, Narsimhaswamy D, Falck JR, Schwartzman ML. 20-HETE mediates endothelial dysfunction via Ikkdependent Enos uncoupling. J Pharmacol Exp Ther. 2009;332:57-65.
21. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, Nasjletti A, Laniado-Schwartzman M. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res. 2006;98:962-969.
22. Inoue K, Sodhi K, Puri N, Gotlinger KH, Cao J, Rezzani R, Falck JR, Abraham NG, Laniado-Schwartzman M. Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol. 2009;297:F875-F884.
23. Zhang F, Wang MH, Krishna UM, Falck JR, Laniado-Schwartzman M, Nasjletti A. Modulation by 20-HETE of phenylephrine-induced mesenteric artery contraction in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 2001;38:1311-1315. (Pubitemid 34033408)
24. Imig JD, Falck JR, Gebremedhin D, Harder DR, Roman RJ. Elevated renovascular tone in young spontaneously hypertensive rats: Role of cytochrome P450. Hypertension. 1993;22:357-364. (Pubitemid 23254084)
25. Nakagawa K, Marji JS, Schwartzman ML, Waterman MR, Capdevila JH. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1055-R1062. (Pubitemid 36406866)
26. Ward NC, Rivera J, Hodgson J, Puddey IB, Beilin LJ, Falck JR, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation. 2004;110:438-443. (Pubitemid 38993854)
27. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;51:1393-1398. (Pubitemid 351555955)
28. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-362.
29. Imaoka S, Yamazoe Y, Kato R, Funae Y. Hormonal regulation of rat cytochrome P450s by androgen and pituitary. Arch Biochem Biophys. 1992;299:179-184.
30. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, Schunck WH. Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J. 2007;403:109-118. (Pubitemid 46569872)
31. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension. 1992;19:456-463.
32. Reckelhoff JF, Granger JP. Role of androgens in mediating hypertension and renal injury. Clin Exp Pharmacol Physiol. 1999;26:127-131.
33. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell. 1998;95:729-731. (Pubitemid 29014451)
34. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-158.
35. Elks CM, Mariappan N, Haque M, Guggilam A, Majid DS, Francis J. Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol. 2009;296:F298-F305.
36. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315:51-57. (Pubitemid 41380497)
37. Ozawa Y, Kobori H. Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. Am J Physiol Renal Physiol. 2007; 293:F100-F109. (Pubitemid 47345008)
38. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001;37: 781-786. (Pubitemid 32199066)
39. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertensioninduced renal damage. Circ Res. 2007;101:268-276. (Pubitemid 47344076)
40. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radic Biol Med. 2005;38:1032-1036. (Pubitemid 40386549)
41. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension. 2005;45: 170-174. (Pubitemid 40179952)